New developments in the management of Anderson‐Fabry disease
Identifieur interne : 009644 ( Main/Exploration ); précédent : 009643; suivant : 009645New developments in the management of Anderson‐Fabry disease
Auteurs : A. Mehta [Royaume-Uni]Source :
- QJM [ 1460-2725 ] ; 2002-10.
Abstract
Anderson‐Fabry disease (AFD) is a rare, X‐linked lysosomal storage disorder that leads to accumulation of globotriasylceramide throughout diverse cells, tissues and organs of the body. The disease usually presents in childhood, is progressive, and results in increasing disability and premature death. Female carriers tend to be less severely affected. AFD is difficult to diagnose because of its heterogeneous signs and symptoms. Awareness is low among health professionals, and diagnosis is typically delayed for several years after first presentation. Treatment was formerly entirely symptomatic, but enzyme replacement therapy has recently been licensed and management is evolving from genetic counselling and palliative care to early diagnosis and active intervention.
Url:
DOI: 10.1093/qjmed/95.10.647
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C03
- to stream Istex, to step Curation: 001C03
- to stream Istex, to step Checkpoint: 002587
- to stream Main, to step Merge: 009A25
- to stream Main, to step Curation: 009644
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">New developments in the management of Anderson‐Fabry disease</title><author wicri:is="90%"><name sortKey="Mehta, A" sort="Mehta, A" uniqKey="Mehta A" first="A." last="Mehta">A. Mehta</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3D35889B6645C165D4B9268238464DD4DA71C34C</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1093/qjmed/95.10.647</idno><idno type="url">https://api.istex.fr/document/3D35889B6645C165D4B9268238464DD4DA71C34C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C03</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C03</idno><idno type="wicri:Area/Istex/Curation">001C03</idno><idno type="wicri:Area/Istex/Checkpoint">002587</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002587</idno><idno type="wicri:doubleKey">1460-2725:2002:Mehta A:new:developments:in</idno><idno type="wicri:Area/Main/Merge">009A25</idno><idno type="wicri:Area/Main/Curation">009644</idno><idno type="wicri:Area/Main/Exploration">009644</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">New developments in the management of Anderson‐Fabry disease</title><author wicri:is="90%"><name sortKey="Mehta, A" sort="Mehta, A" uniqKey="Mehta A" first="A." last="Mehta">A. Mehta</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>From the Department of Haematology, Royal Free Hospital</wicri:orgArea></affiliation></author></analytic><monogr></monogr><series><title level="j">QJM</title><title level="j" type="abbrev">QJM</title><idno type="ISSN">1460-2725</idno><idno type="eISSN">1460-2393</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2002-10">2002-10</date><biblScope unit="volume">95</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="647">647</biblScope><biblScope unit="page" to="653">653</biblScope></imprint><idno type="ISSN">1460-2725</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1460-2725</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Anderson‐Fabry disease (AFD) is a rare, X‐linked lysosomal storage disorder that leads to accumulation of globotriasylceramide throughout diverse cells, tissues and organs of the body. The disease usually presents in childhood, is progressive, and results in increasing disability and premature death. Female carriers tend to be less severely affected. AFD is difficult to diagnose because of its heterogeneous signs and symptoms. Awareness is low among health professionals, and diagnosis is typically delayed for several years after first presentation. Treatment was formerly entirely symptomatic, but enzyme replacement therapy has recently been licensed and management is evolving from genetic counselling and palliative care to early diagnosis and active intervention.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Mehta, A" sort="Mehta, A" uniqKey="Mehta A" first="A." last="Mehta">A. Mehta</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009644 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009644 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3D35889B6645C165D4B9268238464DD4DA71C34C
|texte= New developments in the management of Anderson‐Fabry disease
}}
| This area was generated with Dilib version V0.6.31. |  |